Introduction
An important function of the US Food and Drug Administration (FDA) is to manage and minimize the risk for potential adverse events from approved drugs. FDA Amendments Act of 2007 gave the FDA the authority to mandate incorporation of risk evaluation and mitigation strategies (REMS) for drugs with the potential for harm [1] . All REMS programs must have a "minimal strategy" timetable for assessment at defined intervals, and can also include one or more of the following: medication guide; communication plan; elements to ensure safe use (ETASU); an implementation plan for ETASU [2, 3] . The various elements of REMS programs are designed to ensure safe use of a product and can include: restricted access; healthcare provider or pharmacy certifications; regular monitoring of patients [2, 3] .
The REMS process is evolving, and the lack of standardization often complicates implementation of individual programs [3] . Safest possible use of treatments can be achieved through collaboration of all parties: patient, provider, manufacturer, and the FDA. Recently, the FDA has required REMS programs to include rigid protocols for patient evaluation as a condition for continued dispensation of the covered medication. Protocols may include required laboratory tests and, if pre-specified thresholds are met, termination of the medication is required. These protocols can be valuable in reducing risk to patients but only if they are targeted successfully toward, and adhered to by, the particular patient population at risk for specific adverse events, along with the treating physician. To ensure that the precautions put in place by REMS are being implemented appropriately, adherence to their requirements should be 
Abstract
Background: Risk evaluation and mitigation strategies (REMS), as mandated by the US Food and Drug Administration (FDA) for medications with the potential for harm, are increasingly incorporating rigid protocols for patient evaluation, but little is known about compliance with these programs. Despite the inherent limitations, data on administrative claims may provide an opportunity to investigate adherence to these programs.
Methods:
We assessed adherence to liver function test (LFT) requirements included in the REMS program for bosentan through use of administrative claims. Patients observed in the Optum Research Database who were initiators of bosentan from November 20, 2001 to March 31, 2013 were included. Adherence to LFTs was calculated using pharmacy claims for bosentan dispensation and medical claims for laboratory services, and was assessed at the time of drug initiation and within specified time intervals throughout follow-up.
Results:
Of 742 patients, 523 (70.5%) had ≥1 qualifying LFT. Among patients with ≥12 dispensations, claims for LFTs at individual dispensations were 53.2-64.0%. Median proportion of dispensations with ≥1 LFT was 0.8 among patients with ≥6 (interquartile range, 0.7-1.0) or ≥12 (0.7-0.9) dispensations. Adherence was 90-100% for 33.3% of all initiators, whereas 29.3% of initiators were non-adherent (defined as <50% of on-therapy LFTs). Drugs in Context 2015; 4: 212272 ORIGINAL RESEARCH -Adherence to risk evaluation and mitigation strategies Drugs in Context monitored and, if necessary, actions should be taken to improve deficiencies. Little is known about adherence to REMS programs by patients and providers [4] . The present study was designed to evaluate the level of adherence to specific requirements within a rigid REMS program.
Bosentan is an endothelin receptor antagonist indicated for treatment of pulmonary arterial hypertension (PAH) [5] . Bosentan has one of the most restrictive REMS programs of any medication on the market, including multiple requirements regarding potential risks for hepatotoxicity and birth defects [6] . Bosentan is available only through the Tracleer (bosentan) Access Program (TAP), which requires provider attestation of liver function testing before initiation of bosentan use and patient attestation of monthly assessments during therapy. One element of REMS and the TAP requires providers to have reviewed pretreatment liver function tests (LFTs) and ordered monthly LFTs for anticipated duration of therapy (≤1 year) before first prescribing bosentan to a patient. Despite these requirements for bosentan, a "Dear Doctor" letter was issued in 2006 to report labelling changes based on rare cases of hepatotoxicity as well as to remind providers about the importance and frequency of required LFTs [7] . A more stringent modification of REMS was issued in 2012, which added elements to improve adherence with LFT assessments [6] .
The bosentan REMS program was evaluated in the present study because its rigid protocols for patient assessment and medication access may serve as a model for future program development. In an effort to assess adherence to LFT within this REMS program and changes in adherence after communications and actions regarding regulation of drug safety, we used data based on administrative claims (a common data source for pharmacoepidemiologic studies and evaluation of drug safety).
Methods

Study design
This observational study used data regarding eligibility, pharmacy, and medical claims from the Optum Research Database (ORD), representing patients from a large US health plan. The ORD is a proprietary database with geographically diverse enrollment data from 1993 to the present day. Data relating to ≈12.6 million individuals with medical and pharmacy benefit coverage are available for 2012.
Study population comprised a cohort of patients who received at least one dispensation of bosentan between November 20, 2001 and March 31, 2013 ( Figure 1 ). Patients must have had ≥90 days of medical coverage and pharmacy benefits before cohort entry. Patients also had to be aged <65 years and have no additional public or private insurance. Bosentan dispensations were identified within pharmacy claims through Hierarchical Ingredient Codes Lists. Initiators of bosentan were defined as those with ≥1 pharmacy claim for dispensation of bosentan and no prior dispensation within 90 days. The index date was the date of the first eligible dispensation within the study period. Patients were followed up until the earliest of the following: discontinuation of bosentan therapy, disenrollment, or the end of the study period (March 31, 2013). Discontinuation of bosentan was assumed if the gap between refills exceeded the days supplied plus a 10-day grace period. Therefore, the period of observation for each individual was restricted to the first interval of continuous bosentan therapy.
LFT characterization included laboratory claims for aspartate aminotransferase (AST) and alanine aminotransferase (ALT), as well as for panels that included AST or ALT. Assessments attempted to replicate the monitoring requirements set forth in the bosentan REMS program in how the measure was defined, but the timing was varied conservatively [6] . Laboratory tests for levels of AST and ALT were identified on the basis of Current Procedural Terminology codes for individual tests and for laboratory panels present in outpatient medical claims. ALT, alanine amino transferase; AST, aspartate aminotransferase; CPT, current procedural terminology; LFT, liver function test; REMS, risk evaluation and mitigation strategies; TAP, Tracleer (bosentan) Access Program. Laboratory panels containing ALT and/or AST are commonly ordered during inpatient stays. However, data on inpatient claims do not reliably contain information on specific laboratory tests due to the bundling of service charges. Therefore, inpatient stays of ≥2 days were assumed to include a LFT.
To assess adherence, patient follow-up was divided into mutually exclusive intervals anchored at the time of each bosentan dispensation. Interval lengths were defined as the shorter of either 40 days before dispensation or the time since the previous dispensation. Sensitivity analyses were undertaken using a 35-day interval. LFT adherence associated with the index dispensation of bosentan was assessed over a 90-day interval. Adherence to LFT requirements within REMS was calculated using pharmacy claims for bosentan dispensation and medical claims for laboratory services. Binary indicators of ≥1 LFT were generated for the index dispensation and each subsequent refill. Within patients, adherence to guidelines for LFT monitoring was calculated as the number of bosentan dispensations with an associated prior LFT divided by the total number of bosentan dispensations.
Analyses
Distributions of LFT adherence were analyzed overall and observed by time periods of interest. Analyses were conducted using SAS* 9.2. Distributions were compared, but no formal tests were conducted to evaluate determinants of adherence by statistical means. Reported measures included proportions, means, and standard deviations (SDs), as well as medians and interquartile ranges (IQRs). Characteristics of the study population that were summarized included: demographics; type of provider of index dispensation; medical utilization; medical diagnoses during baseline and follow-up.
Adherence classifications were defined as "high" (90-100%), "moderate" (75-89%), "low" (50-74%), and "non-adherent" (<50%). Adherence per year was evaluated by year of index dispensation (adherence per patient was categorized into the year of the patient's date of initiation). 
Results
Characteristics of the study and Patients
The study population consisted of 742 patients in whom bosentan therapy had been initiated ( Figure 2 ). Among patients considered to be highly adherent, adherence was highest among those who initiated in the years immediately after the initial approval for bosentan, with another peak for those initiating in 2010, for which 41.9% patients were considered to be highly adherent. 
Discussion
In general, REMS initiatives are imperative to ensuring patient safety. Investigation of individual REMS programs can lead to better future programs with the potential to increase patient safety, and permit use of medications that may confer benefit in select populations despite inherent risk. Adherence by physicians and patients to specified requirements is critical to the effectiveness of a REMS program. Hence, we investigated adherence to a restrictive REMS program implemented for providers were cardiologists or pulmonologists. Patients were admitted for a mean of 3 inpatient days, which is consistent with the severity of the primary indication for bosentan. Median number of bosentan dispensations was 4 (IQR, 1.0-9.0) and the distribution time between consecutive dispensations centered on 30 days. Median time between bosentan dispensation and a prior LFT was longer for the index dispensation compared with the median time between dispensation and a prior LFT for the first 12 refills (Table 2 ). However, assessment of the index dispensation was defined as a 90-day interval compared with the 40-day interval for refill dispensations. Mean number of days between dispensation and the most proximal prior LFT was 10.0-13.6.
Adherence to LFTs
Of the 742 patients, 523 (70.5%) had at ≥1 qualifying LFT before the index dispensation (Table 3 ). In the 40-day assessment, among patients with ≥12 dispensations, the percentage of patients with a claim for a LFT was lowest at dispensation number 8 (53.2%) and highest at dispensation number 3 (64.0%). Adherence (defined for each person as the median proportion of dispensations with ≥1 LFT) was 0.8 among patients with ≥6 (IQR 0.7-1.0) or ≥12 (0.7-0.9) dispensations. Among all initiators, 33.3% had high adherence (90-100% of dispensations had a corresponding LFT), whereas 29.3% of all initiators were considered to be non-adherent (<50% of bosentan dispensations had a corresponding LFT). The level An early study following the mandate to authorize the FDA to implement REMS revealed significant concerns among stakeholders from various perspectives -healthcare providers, drug sponsors, patient advocates, payers, and pharmaciststhat REMS would have significant impacts on the healthcare system [2] . Current studies highlight the steps being proposed and taken to improve REMS programs, particularly to standardize programs and evaluate effectiveness [3, 4] . The FDA recently introduced a REMS Integration Initiative to evaluate and improve implementation of REMS programs [8] . 
All initiators (N=742)
Initiators with ≥12 dispensations (n=139) For patients who underwent all 12-treatment cycles (n=228), 61.4% were adherent; this value increased to 64.9% with incorporation of tests during hospitalization. Adherence levels observed in these sensitivity analyses were slightly lower than those observed using the ORD.
≥1 LFT within dispensation-specific assessment intervals, n (%)
Index dispensation 1st refill 2nd refill 3rd refill 4th refill 5th refill 6th refill 7th refill 8th refill 9th refill 10th refill 11th refill 12th
Proportion of dispensations with ≥1 prior LFT while continuously on therapy
All dispensations
It is clear that an ongoing tracking system can provide more accountability and reconciliation of adherence with REMS programs due to the inability of readily available data sources to completely capture non-adherence by patients and physicians. Studies to evaluate these systems are becoming more prevalent. For example, a study covering 2005-2011 for evaluation of asthma medications found that the implemented REMS program resulted in a reduction of use of fluticasone propionate/salmeterol and Risk Management Plan [11] . They found that both provide positive guidance for identifying, monitoring, and minimizing risks to patient safety, but neither provides specific guidance on how risk should be balanced with benefit, either qualitatively or quantitatively [11] . Risk communication is an integral part of REMS programs, but the educational effectiveness of the approach has not been studied extensively. A recent investigation analyzed the approach of adding an Internetbased continuing-medical-education activity, and found improvement in the understanding of specific drug toxicities among healthcare providers [12] .
In the present study, adherence to an example of a stringent program that requires LFT monitoring was investigated utilizing only data on administrative claims. Adherence to REMS requirements for LFT monitoring while on continuous therapy was 70.5%. In the context of the present study, the evidence did not suggest meaningful improvement in adherence following periods defined by FDA inquiries and actions pertaining to LFTs. As sensitivity analyses, data from another database on administrative claims representing a different patient population were assessed. The Truven Health Marketscan Commercial Investigation of REMS programs (and especially adherence to their measures) is necessary. Databases of administrative claims (such as those used in our study) are a convenient and cost-effective method of investigation. However, interpretation of findings based solely on electronic claims should consider the inherent limitations in the processing and accumulation of these data. Claims for LFTs were observed, but claims data do not enable assessment of whether LFTs were reviewed by the provider, or whether the provider responded appropriately to elevated laboratory results, which is required by the REMS and which would provide more complete analyses of adherence. In addition, claims-based data include medication dispensations, but there is no assurance that the medication was taken as prescribed. Furthermore, the ORD includes a large and diverse patient population, but patients within this analytic dataset may not fully represent the patterns of adherence observed in the general population.
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Investigating existing REMS programs with rigid protocols may provide insight on how to accomplish more successful implementation of REMS with similar restrictions. Taking into account the limitations of using claims data, the results of this study indicate less-than-optimal adherence. Joint efforts between the FDA and pharmaceutical companies (including efforts to increase adherence from patients and providers) may make improvement of REMS more successful.
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